Dipeptide-repeat protein detection in C9orf72 neurodegeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively understand and address the pathomechanisms leading to neurodegeneration in patients with C9orf72 hexanucleotide repeat expansions, particularly how these expansions result in characteristic p62-positive/TDP-43-negative inclusions, limiting therapeutic options for FTLD/ALS.
Innovation Solution
Identification of poly-(Gly-Ala), poly-(Gly-Pro), and poly-(Gly-Arg) dipeptide-repeat proteins generated by non-ATG-initiated translation from expanded GGGGCC repeats, facilitating the development of therapeutic approaches to inhibit abnormal protein generation or aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-ATG-initiated translation is used to generate dipeptide-repeat proteins from expanded GGGGCC repeats, then therapeutic targeting of abnormal protein generation becomes possible, but the complexity of detecting and measuring these proteins increases
Solution Approach 1:
The patent employs immunohistochemical staining with specific antibodies that produce visible color changes to detect dipeptide-repeat proteins in tissue sections. This allows visualization and detection of the abnormal proteins through colorimetric methods, making the detection process more accessible despite the complexity of the target proteins.
Solution Approach 2:
The patent uses specific antibodies as intermediary molecules to detect dipeptide-repeat proteins. These antibodies serve as mediators between the target proteins and detection systems, enabling indirect but reliable detection of the abnormal proteins generated by non-ATG-initiated translation.
2Reliability
If dipeptide-repeat proteins are targeted to prevent disease progression, then therapeutic effectiveness may be improved, but the device and treatment complexity increases
Solution Approach 1:
The patent focuses on targeting and eliminating the harmful dipeptide-repeat proteins that are extracted or separated from normal cellular processes. By specifically targeting these abnormal proteins generated by non-ATG-initiated translation, the treatment approach isolates the pathogenic element for targeted intervention.
Solution Approach 2:
The patent identifies and targets specific segments or types of dipeptide-repeat proteins (such as poly-GA, poly-GR, poly-GP) that are generated from the expanded repeats. This segmentation allows for more precise therapeutic targeting of specific pathological proteins rather than attempting to address all proteins simultaneously.
3Measurement precision
If specific antibodies are used to detect dipeptide-repeat proteins, then measurement precision is improved, but the loss of time and resources for developing these detection methods increases
Solution Approach 1:
The patent employs pre-developed specific antibodies against dipeptide-repeat proteins that have been prepared in advance. These preliminary prepared detection tools eliminate the need for developing new detection methods at the point of diagnosis, reducing time loss while maintaining high measurement precision.
Solution Approach 2:
The patent uses antibody copies or clones that specifically recognize dipeptide-repeat proteins. These standardized antibody copies can be reproduced and used across multiple detection applications, reducing the time and resources needed to develop detection methods from scratch for each new application.
Data Source
Figure 1A~1D
Figure 2
Figure 3A~3D
AI summary
The present invention relates to a method of detecting a disease characterized by an expansion of genomic hexanucleotide repeats as well as polypeptides of said hexanucleotide repeats, ligands specifically binding to the polypeptide, methods of identifying an inhibitor preventing the expression and/or aggregation of said polypeptide.